“吉西他滨治疗进展或复发的转移性平滑肌肉瘤患者后使用莫西司他联合吉西他滨的II期研究（SARC018_SPORE02）”勘误
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy".
作者信息
Choy Edwin, Ballman Karla, Chen James, Dickson Mark A, Chugh Rashmi, George Suzanne, Okuno Scott, Pollock Raphael, Patel Rajiv M, Hoering Antje, Patel Shreyaskumar
机构信息
Massachusetts General Hospital, Division of Hematology Oncology, 55 Fruit Street, Boston, MA 02114, USA.
Weill Cornell Medicine Healthcare Policy and Research, 402 East 67th Street, LA-225, New York, NY 10065, USA.
出版信息
Sarcoma. 2019 Aug 27;2019:7608743. doi: 10.1155/2019/7608743. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1155/2018/2068517.].
摘要
[本文更正了文章的数字对象标识符：10.1155/2018/2068517。]
相似文献
1
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy".
Sarcoma. 2019 Aug 27;2019:7608743. doi: 10.1155/2019/7608743. eCollection 2019.
2
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.
Sarcoma. 2018 Oct 24;2018:2068517. doi: 10.1155/2018/2068517. eCollection 2018.
3
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.
Clin Sarcoma Res. 2015 May 16;5:13. doi: 10.1186/s13569-015-0029-8. eCollection 2015.
4
Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Clin Oncol (R Coll Radiol). 2013 Jun;25(6):346-55. doi: 10.1016/j.clon.2012.11.008. Epub 2013 Jan 5.
5
[Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Onkologie. 2005 Mar;28 Suppl 1:1-28. doi: 10.1159/000084364. Epub 2005 Mar 30.
6
Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival.
Turk J Urol. 2017 Sep;43(3):273-278. doi: 10.5152/tud.2017.24478. Epub 2017 Jul 31.
7
Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature.
Int Cancer Conf J. 2017 Sep 11;7(1):11-15. doi: 10.1007/s13691-017-0309-7. eCollection 2018 Jan.
8
Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus.
Case Rep Obstet Gynecol. 2020 Feb 7;2020:4629452. doi: 10.1155/2020/4629452. eCollection 2020.
9
Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer.
Womens Health (Lond). 2005 Nov;1(3):323-9. doi: 10.2217/17455057.1.3.323.
10
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors.
Invest New Drugs. 1998;16(4):325-30. doi: 10.1023/a:1006242005837.
引用本文的文献
1
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
Front Cell Dev Biol. 2020 Sep 29;8:576946. doi: 10.3389/fcell.2020.576946. eCollection 2020.
本文引用的文献
1
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.
Sarcoma. 2018 Oct 24;2018:2068517. doi: 10.1155/2018/2068517. eCollection 2018.
Zotero 插件